Zacharioudakis, Emmanouil
Agianian, Bogos http://orcid.org/0000-0003-1295-6846
Kumar MV, Vasantha
Biris, Nikolaos http://orcid.org/0000-0003-4055-5521
Garner, Thomas P.
Rabinovich-Nikitin, Inna
Ouchida, Amanda T.
Margulets, Victoria
Nordstrøm, Lars Ulrik
Riley, Joel S. http://orcid.org/0000-0001-9170-5716
Dolgalev, Igor http://orcid.org/0000-0003-4451-126X
Chen, Yun
Wittig, Andre J. H.
Pekson, Ryan http://orcid.org/0000-0002-1713-2582
Mathew, Chris
Wei, Peter
Tsirigos, Aristotelis
Tait, Stephen W. G. http://orcid.org/0000-0001-7697-132X
Kirshenbaum, Lorrie A.
Kitsis, Richard N. http://orcid.org/0000-0003-1395-9694
Gavathiotis, Evripidis http://orcid.org/0000-0001-6319-8331
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA178394, P30 CA013330)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (P01AG031782)
Irma T. Hirschl Trust
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (S10OD016305)
Article History
Received: 29 April 2021
Accepted: 10 June 2022
First Online: 7 July 2022
Competing interests
: E.Z., N.B., R.N.K., and E.G. have filled patent applications submitted by Albert Einstein College of Medicine that protects compounds, compositions, and methods for controlling mitofusins for the treatment of diseases and disorders. E.G. is a co-founder and scientific advisor of BAKX Therapeutics, Selphagy Therapeutics now part of Life Biosciences, and Stelexis Therapeutics. None of the above companies have sponsored this research. All other authors declare no competing interests.